Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2013

Open Access 01-12-2013 | Research

Depth of colorectal-wall invasion and lymph-node involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases

Authors: Angelo Di Giorgio, Maurizio Cardi, Daniele Biacchi, Simone Sibio, Fabio Accarpio, Antonio Ciardi, Tommaso Cornali, Marialuisa Framarino, Paolo Sammartino

Published in: World Journal of Surgical Oncology | Issue 1/2013

Login to get access

Abstract

Background

More information is needed on the anatomopathological outcome variables indicating the appropriate surgical strategy for the colorectal resections often needed during cytoreduction for ovarian cancer.

Methods

From a phase-II study cohort including 70 patients with primary advanced or recurrent ovarian cancer with diffuse peritoneal metastases treated from November 2000 to April 2009, we selected for this study the 52 consecutive patients who needed colorectal resection. Data collected included type of colorectal resection, peritoneal cancer index (PCI), histopathology (depth of bowel-wall invasion and lymph-node spread), cytoreduction rate and outcome. Correlations were tested between possible prognostic factors and Kaplan-Meier five-year overall and disease-free survival. A Cox multivariate regression model was used to identify independent variables associated with outcome.

Results

In the 52 patients, the optimal cytoreduction rate was 86.5% (CC0/1). In all patients, implants infiltrated deeply into the bowel wall, in 75% of the cases up to the muscular and mucosal layer. Lymph-node metastases were detected in 50% of the cases; mesenteric nodes were involved in 42.3%. Most patients (52%) had an uneventful postoperative course. Operative mortality was 3.8%. The five-year survival rate was 49.9% and five-year disease-free survival was 36.7%. Cox regression analysis identified as the main prognostic factors completeness of cytoreduction and depth of bowel wall invasion.

Conclusions

Our findings suggest that the major independent prognostic factors in patients with advanced ovarian cancer needing colorectal resections are completeness of cytoreduction and depth of bowel wall invasion. Surgical management and pathological assessment should be aware of and deal with dual locoregional and mesenteric lymphatic spread.
Literature
1.
go back to reference Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 2006, 56: 106-130. 10.3322/canjclin.56.2.106.CrossRefPubMed Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 2006, 56: 106-130. 10.3322/canjclin.56.2.106.CrossRefPubMed
2.
go back to reference Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007, 18: 581-592.CrossRefPubMed Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007, 18: 581-592.CrossRefPubMed
3.
go back to reference Zivanovic O, Aldini A, Carlson JW, Chi DS: Advanced cytoreductive surgery: American perspective. Gynecol Oncol. 2009, Suppl 2: S3-S9.CrossRef Zivanovic O, Aldini A, Carlson JW, Chi DS: Advanced cytoreductive surgery: American perspective. Gynecol Oncol. 2009, Suppl 2: S3-S9.CrossRef
4.
go back to reference Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006, 354: 34-43. 10.1056/NEJMoa052985.CrossRefPubMed Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006, 354: 34-43. 10.1056/NEJMoa052985.CrossRefPubMed
5.
go back to reference Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003, 21: 3194-3200. 10.1200/JCO.2003.02.153.CrossRefPubMed Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003, 21: 3194-3200. 10.1200/JCO.2003.02.153.CrossRefPubMed
6.
go back to reference Winter WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007, 25: 3621-3627. 10.1200/JCO.2006.10.2517.CrossRefPubMed Winter WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007, 25: 3621-3627. 10.1200/JCO.2006.10.2517.CrossRefPubMed
7.
go back to reference Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002, 20: 1248-1259. 10.1200/JCO.20.5.1248.CrossRefPubMed Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002, 20: 1248-1259. 10.1200/JCO.20.5.1248.CrossRefPubMed
8.
go back to reference Piver MS, Baker T: The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol Oncol. 1986, 24: 1-8. 10.1016/0090-8258(86)90001-6.CrossRefPubMed Piver MS, Baker T: The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol Oncol. 1986, 24: 1-8. 10.1016/0090-8258(86)90001-6.CrossRefPubMed
9.
go back to reference Eisenkop SM, Friedman RL, Wang HJ: Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998, 69: 103-108. 10.1006/gyno.1998.4955.CrossRefPubMed Eisenkop SM, Friedman RL, Wang HJ: Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998, 69: 103-108. 10.1006/gyno.1998.4955.CrossRefPubMed
10.
go back to reference Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, Podratz KC, Cliby WA: Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006, 107: 77-85. 10.1097/01.AOG.0000192407.04428.bb.CrossRefPubMed Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, Podratz KC, Cliby WA: Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006, 107: 77-85. 10.1097/01.AOG.0000192407.04428.bb.CrossRefPubMed
11.
go back to reference Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS: The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 2008, 108: 276-281. 10.1016/j.ygyno.2007.10.022.CrossRefPubMed Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS: The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 2008, 108: 276-281. 10.1016/j.ygyno.2007.10.022.CrossRefPubMed
12.
go back to reference du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009, 115: 1234-1244. 10.1002/cncr.24149.CrossRefPubMed du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009, 115: 1234-1244. 10.1002/cncr.24149.CrossRefPubMed
13.
go back to reference Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, Oza AM: Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer. Cancer. 2007, 109: 692-702. 10.1002/cncr.22466.CrossRefPubMed Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, Oza AM: Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer. Cancer. 2007, 109: 692-702. 10.1002/cncr.22466.CrossRefPubMed
14.
go back to reference Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, Tarquini S, Di Seri M, Ciardi A, Montruccoli D, Sammartino P: Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008, 113: 315-325. 10.1002/cncr.23553.CrossRefPubMed Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, Tarquini S, Di Seri M, Ciardi A, Montruccoli D, Sammartino P: Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008, 113: 315-325. 10.1002/cncr.23553.CrossRefPubMed
15.
go back to reference Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL: Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009, 135: 1637-1645. 10.1007/s00432-009-0667-4.CrossRefPubMed Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL: Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009, 135: 1637-1645. 10.1007/s00432-009-0667-4.CrossRefPubMed
16.
go back to reference Helm CW, Richard SD, Pan J, Bartlett D, Goodman MD, Hoefer R, Lentz SS, Levine EA, Loggie BW, Metzinger DS, Miller B, Parker L, Spellman JE, Sugarbaker PH, Edwards RP, Rai SN: Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer. 2010, 20: 61-69. 10.1111/IGC.0b013e3181c50cde.CrossRefPubMed Helm CW, Richard SD, Pan J, Bartlett D, Goodman MD, Hoefer R, Lentz SS, Levine EA, Loggie BW, Metzinger DS, Miller B, Parker L, Spellman JE, Sugarbaker PH, Edwards RP, Rai SN: Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer. 2010, 20: 61-69. 10.1111/IGC.0b013e3181c50cde.CrossRefPubMed
17.
go back to reference Hoffman MS, Zervose E: Colon resection for ovarian cancer: intraoperative decisions. Gynecol Oncol. 2008, Suppl 2: S56-S65.CrossRef Hoffman MS, Zervose E: Colon resection for ovarian cancer: intraoperative decisions. Gynecol Oncol. 2008, Suppl 2: S56-S65.CrossRef
18.
go back to reference Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH, Barakat RR, Chi DS: Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2005, 99: 608-614. 10.1016/j.ygyno.2005.07.112.CrossRefPubMed Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH, Barakat RR, Chi DS: Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2005, 99: 608-614. 10.1016/j.ygyno.2005.07.112.CrossRefPubMed
19.
go back to reference Juretzka MM, Barakat RR: Pelvic cytoreduction with rectosigmoid resection. Gynecol Oncol. 2007, Suppl 1: 40-44.CrossRef Juretzka MM, Barakat RR: Pelvic cytoreduction with rectosigmoid resection. Gynecol Oncol. 2007, Suppl 1: 40-44.CrossRef
20.
go back to reference Gallotta V, Fanfani F, Vizzielli G, Panico G, Rossitto C, Gagliardi ML, Margariti PA, Salerno MG, Zannoni GF, Pacelli F, Scambia G, Fagotti A: Douglas peritonectomy compared to recto-sigmoid resection in optimally cytoreduced advanced ovarian cancer patients: analysis of morbidity and oncological outcome. Eur J Surg Oncol. 2011, 37: 1085-1092. 10.1016/j.ejso.2011.09.003.CrossRefPubMed Gallotta V, Fanfani F, Vizzielli G, Panico G, Rossitto C, Gagliardi ML, Margariti PA, Salerno MG, Zannoni GF, Pacelli F, Scambia G, Fagotti A: Douglas peritonectomy compared to recto-sigmoid resection in optimally cytoreduced advanced ovarian cancer patients: analysis of morbidity and oncological outcome. Eur J Surg Oncol. 2011, 37: 1085-1092. 10.1016/j.ejso.2011.09.003.CrossRefPubMed
21.
go back to reference Jacquet P, Sugarbaker PH: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Peritoneal carcinomatosis: principle of management. Edited by: Sugarbaker PH. 1996, Boston: Kluwer Academic, Volume 82, 359-374.CrossRef Jacquet P, Sugarbaker PH: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Peritoneal carcinomatosis: principle of management. Edited by: Sugarbaker PH. 1996, Boston: Kluwer Academic, Volume 82, 359-374.CrossRef
22.
go back to reference Peritoneal carcinomatosis: principle of management. Edited by: Sugarbaker PH. 1996, Boston: Kluwer Academic, 155-161. Peritoneal carcinomatosis: principle of management. Edited by: Sugarbaker PH. 1996, Boston: Kluwer Academic, 155-161.
24.
go back to reference Bijelic L, Sugarbaker PH: Cytoreduction of the small bowel surfaces. J Surg Oncol. 2008, 97: 176-179. 10.1002/jso.20912.CrossRefPubMed Bijelic L, Sugarbaker PH: Cytoreduction of the small bowel surfaces. J Surg Oncol. 2008, 97: 176-179. 10.1002/jso.20912.CrossRefPubMed
26.
go back to reference Saxena A, Yan TD, Morris DL: A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg. 2010, 34: 70-78. 10.1007/s00268-009-0206-0.CrossRefPubMed Saxena A, Yan TD, Morris DL: A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg. 2010, 34: 70-78. 10.1007/s00268-009-0206-0.CrossRefPubMed
27.
go back to reference O'Hanlan KA, Kargas S, Schreiber M, Burrs D, Mallipeddi P, Longacre T, Hendrickson M: Ovarian carcinoma metastases to gastrointestinal tract appear to spread like colon carcinoma: implications for surgical resection. Gynecol Oncol. 1995, 59: 200-206. 10.1006/gyno.1995.0008.CrossRefPubMed O'Hanlan KA, Kargas S, Schreiber M, Burrs D, Mallipeddi P, Longacre T, Hendrickson M: Ovarian carcinoma metastases to gastrointestinal tract appear to spread like colon carcinoma: implications for surgical resection. Gynecol Oncol. 1995, 59: 200-206. 10.1006/gyno.1995.0008.CrossRefPubMed
28.
go back to reference Lax SF, Petru E, Holzer E, Pertl AM, Ralph G, Greenspan DL, Berger A, Jatzko G: Mesenteric and mesocolic lymph node metastases from ovarian carcinoma: a clinicopathological analysis. Int J Gynecol Cancer. 1998, 8: 119-123. 10.1046/j.1525-1438.1998.09794.x.CrossRef Lax SF, Petru E, Holzer E, Pertl AM, Ralph G, Greenspan DL, Berger A, Jatzko G: Mesenteric and mesocolic lymph node metastases from ovarian carcinoma: a clinicopathological analysis. Int J Gynecol Cancer. 1998, 8: 119-123. 10.1046/j.1525-1438.1998.09794.x.CrossRef
29.
go back to reference Scarabelli C, Gallo A, Franceschi S, Campagnutta E, De G, Giorda G, Visentin MC, Carbone A: Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer. 2000, 88: 389-397. 10.1002/(SICI)1097-0142(20000115)88:2<389::AID-CNCR21>3.0.CO;2-W.CrossRefPubMed Scarabelli C, Gallo A, Franceschi S, Campagnutta E, De G, Giorda G, Visentin MC, Carbone A: Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer. 2000, 88: 389-397. 10.1002/(SICI)1097-0142(20000115)88:2<389::AID-CNCR21>3.0.CO;2-W.CrossRefPubMed
30.
go back to reference Hertel H, Diebolder H, Herrmann J, Köhler C, Kühne-Heid R, Possover M, Schneider A: Is the decision for colorectal resection justified by histopathologic findings: a prospective study of 100 patients with advanced ovarian cancer. Gynecol Oncol. 2001, 83: 481-484. 10.1006/gyno.2001.6338.CrossRefPubMed Hertel H, Diebolder H, Herrmann J, Köhler C, Kühne-Heid R, Possover M, Schneider A: Is the decision for colorectal resection justified by histopathologic findings: a prospective study of 100 patients with advanced ovarian cancer. Gynecol Oncol. 2001, 83: 481-484. 10.1006/gyno.2001.6338.CrossRefPubMed
31.
go back to reference Park JY, Seo SS, Kang S, Lee KB, Lim SY, Choi HS, Park SY: The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol. 2006, 103: 977-984. 10.1016/j.ygyno.2006.06.004.CrossRefPubMed Park JY, Seo SS, Kang S, Lee KB, Lim SY, Choi HS, Park SY: The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol. 2006, 103: 977-984. 10.1016/j.ygyno.2006.06.004.CrossRefPubMed
32.
go back to reference Tebes SJ, Cardosi R, Hoffman MS: Colorectal resection in patients with ovarian and primary peritoneal carcinoma. Am J Obst Gynecol. 2006, 195: 585-589. 10.1016/j.ajog.2006.03.079.CrossRef Tebes SJ, Cardosi R, Hoffman MS: Colorectal resection in patients with ovarian and primary peritoneal carcinoma. Am J Obst Gynecol. 2006, 195: 585-589. 10.1016/j.ajog.2006.03.079.CrossRef
33.
go back to reference Salani R, Diaz-Montes T, Giuntoli RL, Bristow RE: Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma. Ann Surg Oncol. 2007, 14: 3552-3557. 10.1245/s10434-007-9565-7.CrossRefPubMed Salani R, Diaz-Montes T, Giuntoli RL, Bristow RE: Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma. Ann Surg Oncol. 2007, 14: 3552-3557. 10.1245/s10434-007-9565-7.CrossRefPubMed
34.
go back to reference Baiocchi G, Cestari LA, Macedo MP, Oliveira RA, Fukazawa EM, Faloppa CC, Kumagai LY, Badiglian-Filho L, Menezes AN, Cunha IW, Soares FA: Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection. J Surg Oncol. 2011, 104: 250-254. 10.1002/jso.21940.CrossRefPubMed Baiocchi G, Cestari LA, Macedo MP, Oliveira RA, Fukazawa EM, Faloppa CC, Kumagai LY, Badiglian-Filho L, Menezes AN, Cunha IW, Soares FA: Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection. J Surg Oncol. 2011, 104: 250-254. 10.1002/jso.21940.CrossRefPubMed
35.
go back to reference Gouy S, Goetgheluck J, Uzan C, Duclos J, Duvillard P, Morice P: Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer. Eur J Surg Oncol. 2012, 38: 170-175. 10.1016/j.ejso.2011.10.006.CrossRefPubMed Gouy S, Goetgheluck J, Uzan C, Duclos J, Duvillard P, Morice P: Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer. Eur J Surg Oncol. 2012, 38: 170-175. 10.1016/j.ejso.2011.10.006.CrossRefPubMed
36.
go back to reference Dvoretsky PM, Richards KA, Angel C, Rabinowitz L, Stoler MH, Beecham JB, Bonfiglio TA: Distribution of disease at autopsy in 100 women with ovarian cancer. Hum Pathol. 1988, 19: 57-63. 10.1016/S0046-8177(88)80316-2.CrossRefPubMed Dvoretsky PM, Richards KA, Angel C, Rabinowitz L, Stoler MH, Beecham JB, Bonfiglio TA: Distribution of disease at autopsy in 100 women with ovarian cancer. Hum Pathol. 1988, 19: 57-63. 10.1016/S0046-8177(88)80316-2.CrossRefPubMed
37.
go back to reference Pereira A, Magrina JF, Magtibay PM, Pérez-Medina T, Fernández A, Peregrin I: The impact of peritoneal metastases in epithelial ovarian cancer with positive nodes. Int J Gynecol Cancer. 2011, 21: 1375-1379. 10.1097/IGC.0b013e31822fa849.CrossRefPubMed Pereira A, Magrina JF, Magtibay PM, Pérez-Medina T, Fernández A, Peregrin I: The impact of peritoneal metastases in epithelial ovarian cancer with positive nodes. Int J Gynecol Cancer. 2011, 21: 1375-1379. 10.1097/IGC.0b013e31822fa849.CrossRefPubMed
Metadata
Title
Depth of colorectal-wall invasion and lymph-node involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases
Authors
Angelo Di Giorgio
Maurizio Cardi
Daniele Biacchi
Simone Sibio
Fabio Accarpio
Antonio Ciardi
Tommaso Cornali
Marialuisa Framarino
Paolo Sammartino
Publication date
01-12-2013
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2013
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-11-64

Other articles of this Issue 1/2013

World Journal of Surgical Oncology 1/2013 Go to the issue